EUVIMEDEUVIMED entdecken
Crossref

Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes

Tao Yang, Hongling Xu, Cheng Li, Manlin Wang, Xin Zeng, Yongjian Huang, Hongying Abamo, Qiong Man, Yaxin Zheng iD, Yang Li iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.6c00679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Tao Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Chongqing Medical University, Chongqing400016, China. Hauptthemen laut MEDLINE: Liposomes, Imidazoles, Camptothecin, Prodrugs. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Chengdu Medical College Talent Climbing Program, National Natural Science Foundation of China (NSFC), Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effectiveness of liposome-based antitumor drugs is significantly limited by the poor tumor accumulation of liposomes. Herein, we report that resiquimod (R848) can selectively increase tumor accumulation of 7-Ethyl-10-hydroxycamptothecin (SN38)-loaded liposomes (SN38-LIPs) without significantly altering their pharmacokinetics. R848 enhanced the tumor distribution of SN38-LIPs and free SN38 by approximately 5-fold and 10-fold, respectively. This further resulted in greatly improved in vivo antitumor activity compared with those treated with R848 or SN38-LIPs alone (tumor inhibition rate: ∼95% versus ∼50%). The increased antitumor activity was associated with increased serum TNF-α and enhanced macrophage infiltration in the tumor. These results suggested that R848 held great potential to enhance the clinical antitumor effect of nanomedicine by increasing its tumor accumulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesImidazolesCamptothecinProdrugsAntineoplastic AgentsAnimalsIrinotecanMiceHumansCell Line, TumorTumor Necrosis Factor-alphaMacrophagesFemale

Stichwörter der Autor:innen

EPR heterogeneityR848liposomesmacrophage infiltrationtumor accumulationtumor inflammation

Substanzen

LiposomesImidazolesIrinotecanCamptothecinProdrugsresiquimodAntineoplastic AgentsTumor Necrosis Factor-alpharubitecan

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, Chongqing Medical University, Chongqing400016, China.
  • Key Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu610500, China.
  • School of Basic Medicine, Chengdu Medical College, Chengdu, 610500, China.

ORCID-Profile: Yaxin Zheng, Yang Li

Förderung

  • Chengdu Medical College Talent Climbing Program
  • National Natural Science Foundation of China (NSFC)
  • Sichuan Science and Technology Program

Zitieren

APA

Yang, T., Xu, H., Li, C., Wang, M., Zeng, X., Huang, Y., Abamo, H., Man, Q., Zheng, Y., & Li, Y. (2026). Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00679

Vancouver

Yang T, Xu H, Li C, Wang M, Zeng X, Huang Y, et al. Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00679

BibTeX
@article{Yang2026,
  author = {Yang, Tao and Xu, Hongling and Li, Cheng and Wang, Manlin and Zeng, Xin and Huang, Yongjian and Abamo, Hongying and Man, Qiong and Zheng, Yaxin and Li, Yang},
  title = {Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00679}
}
Kostenlos starten →